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Background: Omega-3 (n-3) polyunsaturated fatty acid (PUFA) consumption increases low-density lipoprotein
(LDL) cholesterol (C) concentrations and particle size. Studies showed that individuals with large, buoyant LDL
particles have decreased risk of cardiovascular diseases. However, a large inter-individual variability is observed in LDL
particle size. Genetic factors may explain the variability of LDL-C concentrations and particle size after an n-3 PUFA
supplementation. The monoglyceride lipase (MGLL) enzyme, encoded by the MGLL gene, plays an important role in
lipid metabolism, especially lipoprotein metabolism. The aim of this study was to investigate if polymorphisms (SNPs)
of the MGLL gene influence the variability of LDL-C and LDL particle size in response to an n-3 PUFA supplementation.
Methods: 210 subjects completed the study. They consumed 5 g/d of a fish oil supplement (1.9-2.2 g eicosapentaenoic
acid and 1.1 g docosaexaenoic acid) during 6 weeks. Plasma lipids were measured before and after the supplementation
period and 18 SNPs of the MGLL gene, covering 100% of common genetic variations (minor allele frequency ≥0.05),
have been genotyped using TaqMan technology (Life Technologies Inc., Burlington, ON, CA).
Results: Following the n-3 PUFA supplementation, 55% of subjects increased their LDL-C levels. In a model including the
supplementation, genotype and supplementation*genotype effects, gene-diet interaction effects on LDL-C concentrations
(rs782440, rs6776142, rs555183, rs6780384, rs6787155 and rs1466571) and LDL particle size (rs9877819 and rs13076593)
were observed for the MGLL gene SNPs (p < 0.05).
Conclusion: SNPs within the MGLL gene may modulate plasma LDL-C levels and particle size following an n-3 PUFA
supplementation. This trial was registered at clinicaltrials.gov as NCT01343342.
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Omega-3 (n-3) polyunsaturated fatty acids (PUFA) have
been studied for many years in relation to cardiovascular
diseases (CVD). It has been demonstrated that eicosapenta-
enoic acid (EPA, 20:5n3) and docosahexaenoic acid
(DHA, 22:6n3) consumption from marine sources may
be beneficial in reducing CVD risk and mortality [1-4].
This association may be related in part to the plasma
triglyceride (TG) lowering effect of n-3 PUFA [5-7].
However, less is known about the low-density lipoprotein
(LDL) cholesterol (C) increase following an n-3 PUFA
supplementation that has also been observed in several
studies [8-10]. Elevated LDL-C levels are a major CVD
risk factor [11]. Consequently, reducing LDL-C is a main
therapeutic target in CVD prevention programs, as
recommended by the National Cholesterol Education
Program Adult Treatment Panel III (NCEP-ATPIII)
[12]. However, the cholesterol content of LDL particles is
not the sole issue; LDL particle size may also influence
CVD risk. Actually, large and buoyant particles are less
atherogenic than small and dense particles [13-15]. It has
been proposed that the increase in LDL-C levels caused
by an n-3 PUFA supplementation may be associated with
a shift in the particle distribution from small, dense to
large and buoyant [16-18]. Yet, the results in the literature
are inconsistent. Some studies have found a favourable
shift in the LDL-particle size distribution [17,19-22], while
some others observed an equally distributed elevation of
small and large LDL particles following an n-3 PUFA
supplementation [23-25].
The large inter-individual variability of the metabolic
response to an n-3 PUFA supplementation between
individuals may be caused by genetic factors [26,27].
Single nucleotide polymorphisms (SNPs) have previously
been associated with the variability of plasma lipid
response to an n-3 PUFA intake [28,29].
The monoglyceride lipase (MGLL) enzyme works
together with the hormone-sensitive lipase to hydrolyze
intracellular TG stores in adipocytes, and other cells,
to fatty acids and glycerol. MGLL may also comple-
ment lipoprotein lipase in completing hydrolysis of
monoglycerides resulting from the degradation of lipo-
protein TG [30]. MGLL is also the main contributor
to 2-arachidonoylclycerol (2-AG) degradation, a central
component of the endocannabinoid signaling system
[31]. MGLL is encoded by the MGLL gene, which is
located in chromosome 3. To our knowledge, this
gene has not been studied in relation to blood lipids
or n-3 PUFA intakes yet.
The aim of this study was to test whether single
nucleotide polymorphisms (SNPs) of a gene involved
in TG metabolism could contribute to the n-3 PUFA
supplementation effect on LDL-C levels and particle
size.Methods
Subjects
254 participants were recruited from September 2009 to
December 2011 from the Quebec City metropolitan area
via advertisements in local newspapers and electronic
messages sent to university students and employees.
Subjects had to be aged between 18 and 50 years old, be
non-smokers and free of any thyroid or metabolic disorders
requiring treatment such as diabetes, hypertension, severe
dyslipidemia and coronary heart disease. Their body
mass index (BMI) had to be between 25 and 40 kg/m2.
Participants could not have taken n-3 PUFA supplements
6 months before the beginning of the study. A total of 210
subjects completed the n-3 PUFA supplementation period
and 208 subjects had LDL-C and particle size data
available for further analyses. The ethics committees of
Laval University Hospital Research Center and Laval
University approved this experimental protocol. This trial
was registered at clinicaltrials.gov as NCT01343342.
Study design and diets
Subjects enrolled in the study completed a 2-week run-in
period in which they received individual dietary instructions
by a trained registered dietitian based on Eating Well with
Canada’s Food Guide recommendations. They were asked
to follow these recommendations and to maintain their
body weight stable throughout the protocol. To ensure
stable nutrient intakes, instructions were given regarding
the n-3 PUFA dietary intake: subjects could not exceed two
fish or seafood servings per week, had to prefer white flesh
fishes instead of fatty fishes (examples were given) and
avoid enriched n-3 PUFA food such as milks, juices, breads
and eggs. They were not allowed to consume n-3 PUFA
supplements (such as flaxseed), vitamins or natural health
products during the study. Also, participants had to
limit their alcohol intake during the study to two drinks
per week.
After the 2-week run-in period, each subject received
a bottle containing needed n-3 PUFA capsules for the
following 6 weeks. Then, they were instructed to take
five (1 g fish oil each) capsules per day (Ocean Nutrition,
Nova Scotia, Canada), providing a total of 3–3.3 g of n-3
PUFA (1.9-2.2 g EPA and 1.1 g DHA) per day. Counting
the remaining capsules assessed compliance, as they were
provided in sufficient quantity for 6 weeks. Participants
were asked to report any deviation during the protocol,
their alcohol and fish consumption as well as side effects
if they occurred. Before each phase, subjects received
detailed written and verbal instructions on their diet.
A registered dietitian administered a validated food-
frequency questionnaire (FFQ) to each participant before
the run-in period [32]. This FFQ was based on typical
food items available in Quebec and contained 92 items; 27
items had between 1 and 3 subquestions. The subjects
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per week, per month, or none at all during the month
prior. Many examples of portion sizes were provided to
estimate precisely the portion consumed. Moreover,
participants were instructed on how to complete a 3-day
(two weekdays and one weekend day) food journal
pre- and post-n-3 PUFA supplementation. Dietary intakes
were analysed using Nutrition Data System for Research
software version 2011 (Nutrition Coordinating Center,
University of Minnesota, Minneapolis, MN).
Anthropometric measurements
Body weight, height and waist circumference were
measured according to the procedures recommended
by the Airlie Conference [33] and were taken before the
run-in period as well as pre- and post- n-3 supplementa-
tion. BMI was calculated as weight in kilograms per height
in square meter (kg/m2).
Biochemical parameters
Blood samples were collected from an antecubital vein
into vacutainer tubes containing EDTA after 12 hours
overnight fast and 48 hours alcohol abstinence. Blood
samples were drawn before the run-in period to identify
and exclude participants with metabolic disorders.
Afterwards, selected participants had blood samples taken
before and after the n-3 PUFA supplementation period.
Plasma was separated by centrifugation (2500 x g for
10 min at 4°C) and samples were aliquoted and frozen for
subsequent analyses. Plasma total-cholesterol (TC) and
TG concentrations were measured using enzymatic assays
[34,35]. The high-density lipoprotein cholesterol (HDL-C)
fraction was obtained after precipitation of very low-density
lipoprotein and LDL particles in the infranatant with
heparin manganese chloride [36]. LDL-C was calculated
with the Friedewald formula [37]. Apolipoprotein (Apo)
B-100 concentrations were measured in plasma by the
rocket immunoelectrophoretic method of Laurell [38].
As previously described [15,39], LDL particle size was
obtained by non-denaturing 2–16% polyacrylamide gel
electrophoresis of whole plasma. LDL size was extrapo-
lated from the relative migration of plasma standards of
known diameter [40]. The estimated diameter for the
major peak within each densitometric scan was used to
identify LDL particle size. Analysis of pooled plasma
standards showed that LDL peak measurements and mean
particle diameters were highly reproducible (interassay
coefficients of variation of <2%).
SNP selection and genotyping
SNPs in MGLL were identified with the International
HapMap project SNP database (data release 28, Phase
II + III), based on the National Center for Biotechnology
Information (NCBI assembly B26, dbSNP build 126). TheUtah residents with ancestry from northern and western
Europe (CEU) population was used. Data were re-
trieved and pairwise linkage disequilibrium (LD; R2
values) between SNPs was computed using the Haploview
software V4.2. The tagger selection algorithm was used
to determine tag SNPs from SNPs with a minor allele
frequency (MAF) > 5% (R2 cut-off ≥ 0.8). Afterwards,
we examined LD between 18 SNPs in MGLL covering
all common variations in this gene, using the LD Plot pro-
cedure in Haploview V4.2. A minimum of 85% of the most
common SNPs had to be captured by tag SNPs. ForMGLL,
18 SNPs were sufficient to cover the entire area, with 99%
of the most common SNPs included (Figure 1). The
SIGMA GenElute Gel Extraction Kit (Sigma-Aldrich Co.,
St. Louis, MO, USA) has been used to extract genomic
DNA. DNA was mixed withTaqMan Universal PCR Master
Mix (Life Technologies Inc.), with a gene-specific primer
and with probe mixture (pre-developed TaqMan SNP
Genotyping Assays; Life Technologies Inc.) in a final
volume of 10 μL. Then, genotypes were determined using a
7500 RT-PCR System and analysed using ABI Prism
SDS version 2.0.5 (Life Technologies Inc.). Minor allele
homozygotes with a genotype frequency < 5% were grouped
with heterozygotes for statistical analyses.
Statistical analysis
Statistical analyses were performed with SAS statistical
software V9.2 (SAS Institute, Cary, NC, USA). Subjects
with missing values for calculated LDL-C and for LDL
particle size were excluded from statistical analysis. The
ALLELE procedure was used to verify the departure from
Hardy-Weinberg equilibrium (HWE) and to calculate
MAF. Values that were not normally distributed were
log10-transformed before analyses. ANOVAs were
used to test for significant differences for metabolic
and anthropometric characteristics as well as to test
for differences between various nutrient intakes before
and after the n-3 PUFA supplementation. The MIXED
procedure for repeated measures was used to test for
the effects of the genotype, the supplementation and
the genotype*supplementation interaction on LDL-C
and LDL particle size in a model including age, sex
and BMI. Further adjustments for protein as well as
carbohydrate intakes (at baseline or changes during
the intervention) were also performed. Subjects were
divided in two groups on the basis of their LDL-C levels
variation between pre- and post-supplementation (delta
LDL). Participants who increased their LDL-C levels (≥0%
variation) were assigned to the positive responders group
for LDL-C while those who decreased their LDL-C levels
(<0% variation) were in the negative responders group for
LDL-C. The same was done for LDL particle size vari-
ation. Frequencies of positive responders and negative re-
sponders in the different genotypic groups were calculated
Figure 1 Linkage disequilibrium (LD) plot of selected SNPs in the MGLL gene.
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complex diseases rarely account for a large amount of
variance, characterized by very low p-values (p < 0.001),
we decided to present the results without correction for
multiple testing and using a p-value ≤ 0.05.
Results
Daily energy and nutrient intakes measured by a 3-day
food record are presented in Table 1. After the n-3
PUFA supplementation, saturated fat, carbohydrate and
protein intakes were significantly different from the
pre-supplementation period (p = 0.0008, p = 0.001 and
p = 0.04 respectively). PUFA intakes (including fish oil
capsules and food) were significantly higher after theTable 1 Nutrients intakes before and after n-3 PUFA
supplementation (n = 208)
Nutrients Pre-n-3 PUFA1 Post-n-3 PUFA1 p2
Energy (kcal) 2272 ± 590 2186 ± 566 0.08
Total lipids (g) 84.5 ± 29.2 86.6 ± 29.8 0.47
MUFA (g) 30.8 ± 11.8 29.6 ± 12.4 0.27
PUFA (g) 15.2 ± 6.6 17.1 ± 6.9 0.003*
SFA (g) 29.0 ± 12.0 25.4 ± 10.4 0.0008*
Cholesterol (mg) 303.7 ± 147.4 297.3 ± 169.4 0.65
Carbohydrates (g) 286.7 ± 78.9 263.4 ± 77.7 0.001*
Protein (g) 97.8 ± 30.2 92.6 ± 29.6 0.04*
Alcohol (g) 3.2 ± 6.0 3.2 ± 6.1 0.99
*p < 0.05 1Values are means ± SD, 2ANOVA for the differences between
pre- and post-supplementation, adjusted for age, sex and BMI.supplementation (p = 0.003). Subjects were asked to
limit their fish intake to no more than 2 servings/week
(one serving of fish = 75 g) and the mean intake was
0.89 servings/week for the 6 weeks of the n-3 PUFA
supplementation period. Based on these recommenda-
tions, subjects who had consumed the maximum quantity
of fish permitted each week would have had an extra
0.43 g of EPA +DHA per day.
Biochemical and anthropometric characteristics of
subjects before and after the n-3 PUFA supplementa-
tion are presented in Table 2. Differences in pre- ver-
sus post-supplementation were observed for plasma
TG only. Subjects maintained their body weight, BMI
and waist circumference stable during the protocol.
Moreover, there were no change in plasma TC, HDL-C,
ApoB as well as LDL particle size after the n-3 supple-
mentation. LDL-C levels increased in 55% of subjects,
as illustrated in Figure 2. The mean LDL-C variation
was −0.35 ± 0.31 mmol/L (−12.4 ± 9.8%) in negative re-
sponders and +0.34 ± 0.26 mmol/L (+13.5 ± 10.6%) in
positive responders (mean of all subjects +0.03 ±
0.45 mmol/L (+1.9 ± 16.5%)). The change in LDL-C levels
was not different between men and women after the n-3
PUFA supplementation (data not shown).
All SNPs tested were in HWE (Table 3) and are
located in introns. The MIXED procedure for repeated
measures was used to test for potential interactions
between SNPs of MGLL and the n-3 PUFA supplemen-
tation on blood lipids. Genotype, supplementation and
genotype*supplementation interaction were included in
Table 2 Subjects’ characteristics before and after the n-3
PUFA supplementation (n = 208; Men = 96 (46%) and
Women = 112 (54%))
Pre1 Post1 p2
Age (years) 30.8 ± 8.7
Weight (kg)4 81.0 ± 13.7 81.2 ± 14.0 0.8
BMI (kg/m2)3,4 27.6 ± 3.4 27.7 ± 3.6 0.8
Waist circumference (cm)4 93.0 ± 10.0 93.0 ± 10.1 0.9
Total cholesterol (mmol/L)5 4.72 ± 0.88 4.69 ± 0.91 0.6
HDL (mmol/L)5 1.43 ± 0.35 1.46 ± 0.39 0.3
LDL (mmol/L)5 2.75 ± 0.82 2.77 ± 0.85 0.9
Triglycerides (mmol/L)3,5 1.19 ± 0.62 1.01 ± 0.51 0.0001*
Apolipoprotein B (g/L)5 0.83 ± 0.24 0.86 ± 0.23 0.2
LDL size (Å)5 254.06 ± 2.65 254.21 ± 2.79 0.6
*p < 0.05 1Values are means ± SD, 2ANOVA for the differences before and after
the supplementation, 3Values are log(10) transformed, 4Results adjusted for
age and sex, 5Results adjusted for age, sex and BMI.
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BMI. Plasma TG, total cholesterol and HDL-C levels did
not show any genotype or genotype*supplementation
interactions effects (data not shown). Results for LDL-C
levels and LDL particle size are shown in Tables 4 and 5,
respectively. Only the SNPs with significant values for
either genotype or genotype*supplementation interaction
effects are shown. For LDL-C, neither supplementation
effects nor genotype effects were observed for any of
the SNPs studied. However, six SNPs (rs782440,
rs6776142, rs555183, rs782444, rs6787155, rs1466571) were
significantly interacting with n-3 PUFA supplementa-
tion to modulate plasma LDL-C levels. Furthermore,

















Figure 2 LDL-C variation by subject after the n-3 PUFA supplementat(rs782440, rs13076593, rs549662, rs541855). Three
genotype*supplementation interaction effects were observed
for SNPs of MGLL on LDL particle size (rs782440,
rs9877819, rs13076543). The results remained unchanged
after further adjustments for either energy, PUFA, SFA, pro-
tein or carbohydrate intakes at baseline (data not shown).
After further adjustments for changes in carbohydrate and
protein intake during the supplementation, results remained
the same except for the association between rs78244 and
plasma LDL-C levels that was no longer significant afte
adjustment for changes in protein intake.
Subsequently, genotype frequencies were compared
between positive responders and negative responders as
defined on the basis of their plasma LDL-C response to the
supplementation. Genotype frequency differences were
observed for rs782440, rs555183, rs6780384, rs782444
and rs6787155 (Table 6). For rs782440 and rs555183,
homozygotes for the rare allele were more likely to be nega-
tive responders. For rs6780384, rs782444 and rs6787155,
homozygotes for the major allele were more likely to be
negative responders. Then, we divided the subjects by their
LDL particle size variation. Only one SNP (rs549662)
showed a significant genotype frequency difference as the
minor allele homozygotes were more likely to increase their
LDL particle size (data not shown).
Discussion
In the present study, we tested the effects of MGLL gene
polymorphisms on plasma LDL-C and LDL particle size
following an n-3 PUFA supplementation. The MGLL gene
has been previously shown to be differentially expressed
in peripheral blood mononuclear cells (PBMCs) between
subjects responders and non-responders defined on then=114 (55%)
ion.
Table 3 Selected SNPs of the MGLL gene
dbSNP Sequence MAF1–2 Genotype/Frequency
rs782440 ACCAGC[C/T]TGTGCA 0.50 C/C (n = 53) C/T (n = 105) T/T (n = 52)
0.25 0.50 0.25
rs16826716 GTTTCC[C/T]GTCATG 0.09 C/C (n = 172) C/T (n = 38) T/T (n = 0)
0.82 0.18 0.00
rs6776142 CTGTCA[C/T]GCAGAG 0.33 C/C (n = 91) C/T (n = 98) T/T (n = 21)
0.43 0.47 0.10
rs9877819 ATACAC[A/G]AGGTGT 0.17 G/G (n = 145) A/G (n = 59) A/A (n = 6)
0.69 0.28 0.03
rs555183 AGAGGC[A/G]CCATCA 0.43 A/A (n = 70) A/G (n = 101) G/G (n = 39)
0.33 0.48 0.19
rs6780384 CCTGGG[G/T]AGAAAG 0.10 G/G (n = 168) G/T (n = 40) T/T (n = 2)
0.80 0.19 0.01
rs13076593 TCCAAG[C/G]TAGTAA 0.12 C/C (n = 163) C/G (n = 44) G/G (n = 3)
0.78 0.21 0.01
rs605188 TCTGGG[C/T]GTCTGG 0.42 C/C (n = 72) C/T (n = 98) T/T (n = 40)
0.34 0.47 0.19
rs6765071 CATGAC[C/T]ACGTTC 0.23 C/C (n = 126) C/T (n = 73) T/T (n = 44)
0.60 0.35 0.21
rs782444 GGGCCA[C/T]AGGCAG 0.43 C/C (n = 72) C/T (n = 94) T/T (n = 44)
0.34 0.45 0.21
rs549662 TGCGGT[A/G]AGTGTG 0.17 A/A (n = 145) A/G (n = 59) G/G (n = 6)
0.69 0.28 0.03
rs3773155 CCCCCA[A/G]TCGCAC 0.12 A/A (n = 161) A/G (n = 46) G/G (n = 3)
0.77 0.22 0.01
rs541855 GTGAGA[C/T]GAAAGG 0.18 C/C (n = 139) C/T (n = 65) T/T (n = 6)
0.66 0.31 0.03
rs6439081 ATGCCA[C/T]CACATG 0.24 T/T (n = 121) C/T (n = 78) C/C (n = 11)
0.58 0.37 0.05
rs6439082 CATCCC[C/T]GATCAG 0.15 C/C (n = 154) C/T (n = 49) T/T (n = 7)
0.73 0.23 0.03
rs6787155 CGGACA[A/C]GGTTTA 0.22 A/A (n = 130) A/C (n = 66) C/C (n = 14)
0.62 0.31 0.07
rs1466571 CCAGGT[A/G]AAGAGA 0.33 G/G (n = 91) A/G (n = 98) A/A (n = 21)
0.43 0.47 0.10
rs893294 TGAGGA[A/T]GGATGG 0.34 A/A (n = 93) A/T (n = 91) T/T (n = 26)
0.44 0.43 0.12
1Minor allele frequency.
2Allelic and genotypic frequencies were obtained using the ALLELE procedure in SAS Genetics V9.3.
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post- n-3 PUFA supplementation. 18 SNPs were genotyped
to cover 100% of the common genetic variations. To our
knowledge, this is the first study to examine the influence
of MGLL gene variations on LDL-C levels and LDL
particle size in relation to an n-3 PUFA supplementation.Near half of the subjects increased their LDL-C
levels (55%) and the plasma LDL-C variation ranged
from −1.7 mmol/L to +1.0 mmol/L, which shows the large
inter-individual variability of the LDL-C response to the
n-3 PUFA supplementation observed in this cohort. In
response to dietary interventions, many studies also found
Table 4 Genotype, supplementation and genotype*supplementation interaction effects on LDL-C levels after an n-3
PUFA supplementation
SNP Genotype β (interaction term) P Genotype P Supplementation P Genotype* Supplementation
rs782440 C/C −0.05 0.8 0.1 0.01*
C/T −0.03
T/T 0
rs6776142 C/C 0.11 0.6 0.08 0.008*
C/T 0.05
T/T 0
rs555183 A/A −0.03 0.9 0.1 0.047*
A/G −0.14
G/G 0
rs782444 C/C −0.01 0.8 0.4 0.048*
C/T −0.10
T/T 0
rs6787155 A/A −0.17 0.7 0.8 0.02*
A/C −0.25
C/C 0
rs1466571 A/A −0.08 0.8 0.1 0.02*
A/G −0.07
G/G 0
p-values are derived from log10-transformed data; All results were adjusted for age, sex and BMI; The MIXED procedure in SAS V9.2 was used to test for
interaction effects.
*p<0.05.
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LDL-C. In studies with the National Cholesterol Education
Panel step 2 diets, Schaefer et al. found a plasma LDL-C
variation ranging between +13% and −55% between
participants [41]. A review also showed that LDL-C variedTable 5 Genotype, supplementation and genotype*suppleme
n-3 PUFA supplementation
SNP Genotype β (interaction term) P Genoty
rs782440 C/C −1.57 0.03*
C/T −1.09
T/T 0
rs9877819 A/A + A/G 0 0.2
G/G 0.92
rs13076593 C/C 1.50 0.006*
C/G + G/G 0
rs549662 A/A −1.13 0.02*
A/G + G/G 0
rs3773155 A/A −0.34 0.8
A/G + G/G 0
rs541855 C/C 1.19 0.006*
C/T + T/T 0
p-values are derived from log10-transformed data; All results were adjusted for age
interaction effects.
*p<0.05.from +17% to +46% in hypertriglyceridemic subjects
receiving 4 g/day of n-3 PUFA [42]. We also found that
the LDL particle size was not statistically different in pre-
versus post-supplementation period in our study, while
many studies found an increase in the LDL particle sizentation interaction effects on LDL particle size after an







, sex and BMI; The MIXED procedure in SAS V9.2 was used to test for
Table 6 Differences in genotype frequencies of five SNPs according to the subject’s plasma LDL-C response to an n-3
PUFA supplementation
SNP Homozygotes (wild-type) Heterogygotes Homozygotes (rare) p1
P-Responders N-responders P-Responders N-responders P-Responders N-responders
rs782440 23 (11%) 30 (14%) 56 (27%) 47 (23%) 15 (7%) 37 (18%) 0.01
rs555183 27 (13%) 42 (20%) 54 (26%) 46 (22%) 13 (6%) 26 (13%) 0.04
rs6780384 68 (33%) 99 (47%) 26 (13%) 13 (6%) 0 (0%) 2 (1%) 0.006
rs782444 23 (11%) 48 (23%) 48 (23%) 45 (22%) 23 (11%) 21 (10%) 0.03
rs6787155 49 (24%) 80 (38%) 38 (18%) 27 (13%) 7 (3%) 7 (3%) 0.02
1chi-square test in SAS 9.2.
P (positive) responders versus N (negative) responders.
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earlier. It has been described earlier that the LDL particle
size is inversely related to plasma TG concentrations [43].
In a study by Griffin et al., altering the n-6/n-3 ratio by
giving PUFA enriched diet to subjects has been found to
decrease TG levels as well as the proportion of small,
dense LDL particles [17]. In addition, Kelley et al. showed
a decrease in TG levels and a increase in LDL particle size
following a DHA supplementation in hypertriglyceridemic
men [21]. The TG levels in our cohort decreased by 11%,
as reported previously [44], compared to a mean of 25%
decreased following 3–4 g/day n-PUFA in normolipemic
subjects in a meta-analysis [45]. This may potentially
explain the lack of difference in LDL particle size after the
n-3 PUFA supplementation. Dietary intakes in relation
to LDL particle size variation have been studied by
Faghihnia et al. reporting that a low-fat, high-carbohydrate
diet reduces LDL particle size [46]. However, in the present
study, results remained unchanged after further adjustment
for dietary intakes. The lack of difference in effect of
the n-3 PUFA supplementation on LDL particle size
may also be attributable to the large inter-variability
observed in the plasma TG levels in our study cohort,
as previously reported [47].
We verified the independent effects of supplementation
and genotype as well as the supplementation*genotype
interaction effects on LDL-C and LDL particle size. No
supplementation or genotype effects were observed for
LDL-C. However, six SNPs (rs782440, rs6776142, rs555183,
rs782444, rs6787155, rs1466571) of MGLL showed signifi-
cant supplementation*genotype effects on LDL-C, suggest-
ing that these variants may modulate the LDL-C response
to an n-3 PUFA supplementation. Four SNPs of MGLL
(rs782440, rs13076593, rs549662, rs541855) were associated
with LDL particle size. The T/T carriers for the rs782440
SNP, the C/C for rs13076593, the A/G +G/G genotypes
combined for rs549662 and the C/C genotype for rs541855
had a beta value of 0 or higher for LDL particle size
comparatively to the other genotype groups. Three
SNPs showed a supplementation*genotype interaction
(rs782440, rs9877819, rs13076543). The rs782440 SNPis present in all these statistical associations. To our
knowledge, genetic variants of MGLL have only been
studied once in the literature in relation to meta-
bolic outcomes in humans. An association study of
Harismendy et al. showed that in a population of obese
individuals as well as non-obese controls, three intervals
of rare variants in the MGLL gene sequence are associated
with BMI (promoter, intron 2 and intron 3) [48].
The MGLL enzyme is known to hydrolyse 2-AG, which
is one of the central components of the endocannabinoid
signaling network [31]. The activation of the cannabinoid
receptors by 2-AG have an impact on energy homeostasis
by stimulating appetite, promoting lipid storage and
reducing energy expenditure. They have also been associ-
ated with metabolic changes associated with obesity and
metabolic syndrome [49]. Circulating 2-AG levels in the
plasma have been correlated positively with BMI and waist
girth, as well as with plasma TG levels [50], while another
study found that 2-AG levels were increased by 52% in
obese women [51]. These higher levels of 2-AG in obese
individuals may result of a reduced enzymatic degradation
by the MGLL enzyme. Although we did not find any
associations between MGLL SNPs and BMI or waist
circumference, these measures have been strongly
associated to plasma lipid levels [52] and LDL particle
features [53]. However, a study with MGLL-KO mice
showed that despite an elevation of 2-AG levels, animals
did not have enhanced lipid storage, increased appetite or
decreased energy expenditure [54].
The allele frequency disparities observed between the
different genotype groups and the positive responder/
negative responder status for LDL-C variation suggests
that individuals with different genotypes for these SNPs
may respond differently to an n-3 PUFA supplementation.
Conclusion
In conclusion, we did not found any effect of the n-3
PUFA supplementation on plasma LDL-C concentrations
and LDL particle size after six weeks, but we observed a
large inter-individual variability in the LDL-C response to
the supplementation. Also, this study suggests that SNPs
Ouellette et al. Lipids in Health and Disease 2014, 13:86 Page 9 of 10
http://www.lipidworld.com/content/13/1/86within the MGLL gene modulate LDL-C and particle size
during an n-3 PUFA supplementation. Specific genotypes
also seem to influence the variation in LDL-C levels
following the supplementation. However, further investi-
gation will be needed to fully explain the complex interac-
tions underlying these associations.
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